Article
Gastroenterology & Hepatology
Anna Kan, Shuang Liu, Minke He, Dongsheng Wen, Haijing Deng, Lichang Huang, Zhicheng Lai, Yexing Huang, Ming Shi
Summary: This study reveals the correlation between the transcription factor MZF1 and the immune checkpoint molecule PD-L1 in hepatocellular carcinoma (HCC). The overexpression of MZF1 is associated with an immunosuppressive environment and decreased T-cell infiltration in HCC. Mechanistically, MZF1 accelerates PD-L1 ubiquitination via the CDK4 pathway. Inhibition of CDK4 may restore PD-L1 expression and enhance the efficacy of anti-PD-L1 antibodies.
Review
Immunology
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli
Summary: Hepatocellular carcinoma is a common and deadly cancer around the world. Traditional treatments like surgery, radiotherapy, and targeted therapies have been used, but due to the immune suppressive nature of HCC, immunotherapy with immune checkpoint inhibitors has shown great promise in recent clinical studies.
Article
Immunology
Ze Zhang, Jin Shang, Bingyang Hu, Huizhong Shi, Yinbiao Cao, Junfeng Li, Tianyu Jiao, Wenwen Zhang, Shichun Lu
Summary: This study aimed to screen and identify lncRNAs associated with pyroptosis in HCC patients and developed a prognostic model. The analysis showed that the model could serve as an independent prognostic factor and assess the tumor immune microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Urology & Nephrology
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y. C. Heng, Toni K. Choueiri
Summary: This study found that upfront cytoreductive nephrectomy (CN) is associated with improved clinical outcomes and overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors or targeted therapy. This suggests that upfront CN still has a significant role for selected patients in the era of immune checkpoint inhibitors.
Article
Materials Science, Multidisciplinary
Chunmei Zhang, Yandi Tan, Ju Huang, Xinyi Tang, Hongwei Xiang, Bin Shen, Chenchen Tang, Rui Li
Summary: The clinical success of immune checkpoint inhibitors in the treatment of metastatic cancer has been limited in pretreated metastatic breast cancer due to low immunogenicity and immunosuppressive tumor microenvironment. In this study, nanoliposomes were synthesized to deliver diclofenac and Mn (5,10,15,20-tetrakis(4-chlorophenyl)porphyrin) Cl to overcome these challenges. The results showed that this approach improved the antitumor effect of anti-PD1-based immunotherapy by activating T cells, inactivating regulatory T cells, and regulating immune cytokine levels.
MATERIALS & DESIGN
(2023)
Review
Chemistry, Medicinal
Daniel M. Girardi, Jana Priscila M. Pacifico, Fernanda P. L. Guedes de Amorim, Gustavo dos Santos Fernandes, Marcela C. Teixeira, Allan A. L. Pereira
Summary: With the development of immunotherapy and novel targeting agents, the treatment of advanced hepatocellular carcinoma has significantly improved. Treatment regimens involving the combination of immune checkpoint inhibitors and targeted therapies have shown better outcomes.
Review
Oncology
Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce, Girolamo Ranieri
Summary: Hepatocellular carcinoma is the most common primary liver cancer with poor prognosis. New molecular targeted therapies have shown promising results in recent years. However, research into new treatments is still necessary.
Review
Oncology
Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu
Summary: Hepatocellular carcinoma (HCC) is a significant global health issue, and targeted therapy has made a breakthrough in treating advanced HCC. The combination of targeted therapy with immune checkpoint inhibitors shows more potent anticancer effects.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Stephanie. A. A. Berg, Bradley. A. A. McGregor
Summary: This article discusses the treatment options and methods for clear cell renal cell carcinoma after radical nephrectomy. Currently, oral vascular endothelial growth factor receptor tyrosine kinase inhibitors or intravenous immune checkpoint inhibitors are the approved treatments, although they can cause toxic reactions. Multiple clinical trials are currently underway to explore the role of adjuvant treatment after nephrectomy, and biomarkers may help determine the effectiveness of treatments for patients.
Review
Biochemistry & Molecular Biology
Munawaer Muaibati, Abasi Abuduyilimu, Tao Zhang, Yun Dai, Ruyuan Li, Fanwei Huang, Kexin Li, Qing Tong, Xiaoyuan Huang, Liang Zhuang
Summary: Ovarian cancer is a deadly female reproductive system tumor with a complex immunosuppressive microenvironment. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors but have shown limited benefits in ovarian cancer. Therefore, a comprehensive understanding of immune checkpoint mechanisms is needed to improve the efficacy of ICIs in ovarian cancer.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2023)
Article
Immunology
Huiyang Yuan, Xin Qin, Jing Wang, Qingya Yang, Yidong Fan, Dawei Xu
Summary: This study identified the clinical implications of cuproptosis in clear cell renal cell carcinoma (ccRCC) and constructed a gene signature score system (CuAGS-13) that can predict patients' survival, recurrence, and response to treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Shuo Hong, Yueming Zhang, Manming Cao, Anqi Lin, Qi Yang, Jian Zhang, Peng Luo, Linlang Guo
Summary: A four-gene hypoxia risk model was developed to evaluate the degree of hypoxia and prognosis of ICI treatment in metastatic urothelial carcinoma, showing promising clinical prediction value. The model revealed a close relationship between hypoxia and the tumor immune microenvironment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Ilaria Elia, Jared H. Rowe, Sheila Johnson, Shakchhi Joshi, Giulia Notarangelo, Kiran Kurmi, Sarah Weiss, Gordon J. Freeman, Arlene H. Sharpe, Marcia C. Haigis
Summary: This study reveals the mechanism by which tumor-derived lactate in the tumor microenvironment inhibits the cytotoxicity of CD8(+) T cells, highlighting the role of metabolic pathways in regulating T cell cytotoxicity.
Review
Biochemistry & Molecular Biology
Jun-Yan Li, Yu-Pei Chen, Ying-Qin Li, Na Liu, Jun Ma
Summary: The development of immune checkpoint blockade-based immunotherapy has changed cancer treatment methods significantly, although not all patients can benefit from it. Conventional chemotherapy and targeted therapy can enhance antitumor immune responses, providing a theoretical basis for combination therapy with ICBs, but the optimal treatment regimens still need further exploration.
Article
Oncology
Wenqin Feng, Anqi Lin, Le Sun, Ting Wei, Haoxuan Ying, Jian Zhang, Peng Luo, Weiliang Zhu
Summary: Immune checkpoint inhibitors (ICIs) have achieved significant breakthroughs in anti-tumor therapy, but there is currently no accurate biomarker for predicting their efficacy. This study explores the relationship between CXCR3 pathway activation and the effectiveness of ICIs in patients with metastatic urothelial carcinoma (mUC). It reveals that patients with high CXCR3 expression are more sensitive to ICI treatment, have better prognosis, higher levels of immune cell activation, and higher tumor neoantigen burden.
CANCER CELL INTERNATIONAL
(2022)